The Motley Fool investment advice team is running a little opinion piece on MSNBC. The topic? Exubera, Pfizer's inhalable insulin product, which is all set to enter the US pharmaceuticals market this summer. Like many market analysts, the author Stephen D. Simpson is intrigued by all the fuss and hype surrounding the drug. The thing that strikes me as funny, the more I read about Exubera, is that the drug seems to be a popular topic of discussion for people interested in finance and investment. That is, they are tracking this drug more avidly than are people likely to be prescribing or taking it!
The reason, of course, is money. Will it or won't it be the moneymaker it's projected to be? Interestingly, Simpson's not sure. He says he's never seen as much uncertainty about a drug -- that some predict it will be a goldmine for investors and a diabetes care revolution, while others say it is so overpriced that most diabetics will stick with shots, thanks very much. Simpson's final word: money will be made, even if the market response is officially lower than estimated.
